Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands: Endophthalmitisprophylaxe bei intravitrealer operativer Medikamenteneingabe (IVOM) (Stand Juli 2013)^[*]

 

 Buy Article Permissions and Reprints

Rezente Ergebnisse klinischer Studien geben Anlass dazu, die Rolle der prä- oder postoperativen topischen Antibiotikagabe nach intravitrealen Injektionen zur Endophthalmitisprophylaxe neu zu bewerten. Da eine solche Prophylaxe u. a. in der Fachinformation von Lucentis® [1] empfohlen wird, bestehen Bedenken auch vor juristischen Konsequenzen, falls bei Auftreten einer Endophthalmitis keine topische Antibiotikagabe angewandt wurde.

^* Dieser Beitrag wird ebenfalls in der Zeitschrift Der Ophthalmologe, Springer-Verlag Berlin Heidelberg 2013, 10.1007/s00347-013-2946-3 veröffentlicht.

• Literatur

• 1 Fachinformation Lucentis®. Novartis Pharma; 2012
  Google Scholar
• 2 McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina (Philadelphia, Pa ) 2011; 31: 654-661
  CrossrefPubMedGoogle Scholar
• 3 Moshfeghi AA, Rosenfeld PJ, Flynn jr. HW et al. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center. Retina (Philadelphia, Pa ) 2011; 31: 662-668
  CrossrefPubMedGoogle Scholar
• 4 Bhavsar AR, Stockdale CR, Ferris 3rd FL et al. Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics. Arch Ophthalmol 2012; 130: 809-810
  CrossrefPubMedGoogle Scholar
• 5 Bhavsar AR, Googe jr. JM, Stockdale CR et al. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol 2009; 127: 1581-1583
  CrossrefPubMedGoogle Scholar
• 6 Bhavsar AR, Ip MS, Glassman AR. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol 2007; 144: 454-456
  CrossrefPubMedGoogle Scholar
• 7 Bhatt SS, Stepien KE, Joshi K. Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate. Retina (Philadelphia, Pa ) 2011; 31: 2032-2036
  CrossrefPubMedGoogle Scholar
• 8 Meyer CH, Mennel S, Eter N. [Incidence of endophthalmitis after intravitreal Avastin injection with and without postoperative topical antibiotic application]. Ophthalmologe 2007; 104: 952-957
  CrossrefPubMedGoogle Scholar
• 9 Cheung CS, Wong AW, Lui A et al. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology 2012; 119: 1609-1614
  CrossrefPubMedGoogle Scholar
• 10 Ziemssen F, Dietz K, Bartz-Schmidt KU. [Postoperative antibiotics after intravitreal injection?]. Ophthalmologe 2008; 105: 180-181 author reply 181–182
  CrossrefPubMedGoogle Scholar
• 11 Ziemssen F, Bartz-Schmidt KU. Topical antibiotics to reduce the risk of endophthalmitis after intravitreal injection?. Arch Ophthalmol 2010; 128: 1222-1223 author reply 1223–1224
  PubMedGoogle Scholar
• 12 Stewart MW, Stewart ML. Topical azithromycin or ofloxacin for endophthalmitis. Clin Ophthalmol Auckl Nz 2013; 7: 35-36
  PubMedGoogle Scholar
• 13 Brucker A. Risk of Endophthalmitis after intravitreal Drug Injections with and without Use of topical Antibiotics. Ft. Lauderdale, Florida: IOVS; 2012
  CrossrefGoogle Scholar
• 14 Nentwich M, Yactayo-Miranda Y, Weimann S et al. Bacterial contamination of needle points after intravitreal injection. Eur J Ophthalmol 2009; 19: 268-272
  PubMedGoogle Scholar
• 15 Gines JC, Nentwich MM, Peggy Bedoya AH et al. [Bacterial contamination of needles after intravitreal injection in Paraguay]. Ophthalmologe 2012; 109: 782-787
  CrossrefPubMedGoogle Scholar
• 16 Friedman DA, Mason 3rd JO, Emond T et al. Povidone-iodine contact time and lid speculum use during intravitreal injection. Retina (Philadelphia, Pa ) 2013; 33: 975-981
  CrossrefPubMedGoogle Scholar
• 17 Pilli S, Kotsolis A, Spaide RF et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008; 145: 879-882
  CrossrefPubMedGoogle Scholar
• 18 Artunay O, Yuzbasioglu E, Rasier R et al. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye 2009; 23: 2187-2193
  CrossrefPubMedGoogle Scholar
• 19 Aiello LP, Brucker AJ, Chang S et al. Evolving guidelines for intravitreous injections. Retina (Philadelphia, Pa ) 2004; 24 (5 Suppl) S3-S19
  CrossrefPubMedGoogle Scholar
• 20 German Ophthalmological Society, Retinological Society, Professional Association of German Ophthalmologists. [Statement of the German Ophthalmological Society, the Retinological Society and the Professional Association of German Ophthalmologists on therapy for macular oedema in cases of retinal vein occlusion]. Klin Monatsbl Augenheilkd 2010; 227: 542-556
  Article in Thieme ConnectPubMedGoogle Scholar
• 21 Jaissle GB, Szurman P, Bartz-Schmidt KU. [Recommendation for the implementation of intravitreal injections – statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA)]. Klin Monatsbl Augenheilkd 2005; 222: 390-395
  Article in Thieme ConnectPubMedGoogle Scholar
• 22 Speaker MG, Menikoff JA. Postoperative endophthalmitis: pathogenesis, prophylaxis, and management. Int Ophthalmol Clin 1993; 33: 51-70
  CrossrefPubMedGoogle Scholar
• 23 Simunovic MP, Rush RB, Hunyor AP et al. Endophthalmitis following intravitreal injection versus endophthalmitis following cataract surgery: clinical features, causative organisms and post-treatment outcomes. Br J Ophthalmol 2012; 96: 862-866
  CrossrefPubMedGoogle Scholar
• 24 Moss JM, Sanislo SR, Ta CN. A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections. Ophthalmology 2009; 116: 1498-1501
  CrossrefPubMedGoogle Scholar
• 25 Nentwich MM, Rajab M, Ta CN et al. Application of 10 % povidone iodine reduces conjunctival bacterial contamination rate in patients undergoing cataract surgery. Eur J Ophthalmol 2012; 22: 541-546
  CrossrefPubMedGoogle Scholar
• 26 Isenberg SJ, Apt L, Yoshimori R et al. Chemical preparation of the eye in ophthalmic surgery. IV. Comparison of povidone-iodine on the conjunctiva with a prophylactic antibiotic. Arch Ophthalmol 1985; 103: 1340-1342
  CrossrefPubMedGoogle Scholar
• 27 Ness T, Kern WV, Frank U et al. Postoperative nosocomial endophthalmitis: is perioperative antibiotic prophylaxis advisable? A single centreʼs experience. J Hosp Infect 2011; 78: 138-142
  CrossrefPubMedGoogle Scholar
• 28 Ta CN, Egbert PR, Singh K et al. Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacin prophylaxis for cataract surgery. Ophthalmology 2002; 109: 2036-2040 discussion 2040–2041
  CrossrefPubMedGoogle Scholar
• 29 Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update. Ophthalmology 2002; 109: 13-24
  CrossrefPubMedGoogle Scholar
• 30 Behrens-Baumann W, Augustin AJ, Dick B et al. Leitlinie zur Prophylaxe und Therapie von Endophthalmitiden. Hyg Med 2005; 30: 342-362
  PubMedGoogle Scholar
• 31 Barry P, Behrens-Baumann W, Pleyer U et al. ESCRS Guidelines on prevention, investigation and management of post-operative endophthalmitis. Dublin: European Society for Cataract and Refractive Surgery; 2007: 1-36
  CrossrefGoogle Scholar
• 32 Kramer A, Wilhelm F. Antimikrobielle Maßnahmen zur Vorbereitung von Hornhauttransplantaten. In: Wilhelm F, Duncker G, Adewoyin T, Hrsg. Augenbanken. Berlin: Walter de Gruyter; 2002: 52-56
  CrossrefGoogle Scholar
• 33 Wagner D, Scharlach M, Ziehm D. Antibiotikaresistenzen nehmen zu. Niedersächsisches Ärzteblatt 2012; 8
  PubMedGoogle Scholar
• 34 Ebner W. Entwicklung von Antibiotikaresistenzen in Europa. Z prakt Augenheilkunde 2012; 33: 393-396
  PubMedGoogle Scholar
• 35 Razavi B, Zollinger R, Kramer A et al. Systemic iodine absorption associated with the use of preoperative ophthalmic antiseptics containing iodine. Cutan Ocul Toxicol 2013; 32: 279-282
  CrossrefPubMedGoogle Scholar
• 36 Ness T. [Multiresistant bacteria in ophthalmology]. Ophthalmologe 2010; 107: 318-322
  CrossrefPubMedGoogle Scholar
• 37 Alabiad CR, Miller D, Schiffman JC et al. Antimicrobial resistance profiles of ocular and nasal flora in patients undergoing intravitreal injections. Am J Ophthalmol 2011; 152: 999-1004.e2
  CrossrefPubMedGoogle Scholar
• 38 Kim SJ, Toma HS. Antimicrobial resistance and ophthalmic antibiotics: 1-year results of a longitudinal controlled study of patients undergoing intravitreal injections. Arch Ophthalmol 2011; 129: 1180-1188
  CrossrefPubMedGoogle Scholar
• 39 Kim SJ, Toma HS. Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections. Ophthalmology 2011; 118: 1358-1363
  PubMedGoogle Scholar
• 40 Yin VT, Weisbrod DJ, Eng KT et al. Antibiotic resistance of ocular surface flora with repeated use of a topical antibiotic after intravitreal injection. JAMA Ophthalmol 2013; 131: 456-461
  CrossrefPubMedGoogle Scholar
• 41 Dave SB, Toma HS, Kim SJ. Changes in ocular flora in eyes exposed to ophthalmic antibiotics. Ophthalmology 2013; 120: 937-941
  CrossrefPubMedGoogle Scholar
• 42 Dave SB, Toma HS, Kim SJ. Ophthalmic antibiotic use and multidrug-resistant staphylococcus epidermidis: a controlled, longitudinal study. Ophthalmology 2011; 118: 2035-2040
  CrossrefPubMedGoogle Scholar
• 43 Milder E, Vander J, Shah C et al. Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection. Ophthalmology 2012; 119: 1420-1424
  CrossrefPubMedGoogle Scholar
• 44 Miller D, Flynn PM, Scott IU et al. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch Ophthalmol 2006; 124: 479-483
  CrossrefPubMedGoogle Scholar
• 45 Miño De Kaspar H, Hoepfner AS, Engelbert M et al. Antibiotic resistance pattern and visual outcome in experimentally-induced Staphylococcus epidermidis endophthalmitis in a rabbit model. Ophthalmology 2001; 108: 470-478
  CrossrefPubMedGoogle Scholar
• 46 Stille W, Brodt HR, Groll A et al. Antibiotika-Therapie: Klinik und Praxis der antiinfektiösen Behandlung. 12.. Aufl. Stuttgart: Schattauer; 2012
  Google Scholar
• 47 Behrens-Baumann W, Frank U, Ness T. [Rational antibiotic therapy in ophthalmology]. Ophthalmologe 2010; 107: 323-327
  CrossrefPubMedGoogle Scholar
• 48 Lachapelle J-M. Allergic contact dermatitis from povidone-iodine: a re-evaluation study. Contact Dermatitis 2005; 52: 9-10
  CrossrefPubMedGoogle Scholar
• 49 Hansmann F, Kramer A, Ohgke H et al. [Lavasept as an alternative to PVP-iodine as a preoperative antiseptic in ophthalmic surgery. Randomized, controlled, prospective double-blind trial]. Ophthalmologe 2005; 102: 1043-1046 1048–1050
  CrossrefPubMedGoogle Scholar
• 50 Haller JA, Bandello F, Belfort R et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118: 2453-2460
  CrossrefPubMedGoogle Scholar
• 51 Haller JA, Bandello F, Belfort R et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134-1146 e3
  CrossrefPubMedGoogle Scholar
• 52 Lowder C, Belfort jr. R, Lightman S et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129: 545-553
  CrossrefPubMedGoogle Scholar
• 53 Schmitz K, Maier M, Clemens CR et al. [Reliability and safety of intravitreal Ozurdex injections: The ZERO study.]. Ophthalmologe 2013; Apr 6 [Epub ahead of print]
  PubMedGoogle Scholar
• 54 Bezatis A, Spital G, Höhn F et al. Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up – The SOLO study. Acta Ophthalmol 2013; 91: e340-e347
  CrossrefPubMedGoogle Scholar
• 55 Augustin A, Holz F, Meyer W et al. A retrospective data collection study in patients receiving two or more OZURDEX® injections for macular oedema secondary to retinal vein occlusion, 4615/S104. Mailand: Euretina; 2012
  CrossrefGoogle Scholar
• 56 Pearson PA, Comstock TL, Ip M et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011; 118: 1580-1587
  CrossrefPubMedGoogle Scholar
• 57 Jain N, Stinnett SS, Jaffe GJ. Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results. Ophthalmology 2012; 119: 132-137
  CrossrefPubMedGoogle Scholar
• 58 Kempen JH, Altaweel MM, Holbrook JT et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology 2011; 118: 1916-1926
  CrossrefPubMedGoogle Scholar
• 59 Jager RD, Aiello LP, Patel SC et al. Risks of intravitreous injection: a comprehensive review. Retina (Philadelphia, Pa ) 2004; 24: 676-698
  CrossrefPubMedGoogle Scholar
• 60 Moshfeghi AA, Scott IU, Flynn jr. HW et al. Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol 2004; 138: 489-492
  CrossrefPubMedGoogle Scholar
• 61 Moshfeghi DM, Kaiser PK, Bakri SJ et al. Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging 2005; 36: 24-29
  PubMedGoogle Scholar
• 62 Moshfeghi DM, Kaiser PK, Scott IU et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003; 136: 791-796
  CrossrefPubMedGoogle Scholar
• 63 Westfall AC, Osborn A, Kuhl D et al. Acute endophthalmitis incidence: intravitreal triamcinolone. Arch Ophthalmol 2005; 123: 1075-1077
  CrossrefPubMedGoogle Scholar
• 64 Nelson ML, Tennant MTS, Sivalingam A et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina (Philadelphia, Pa ) 2003; 23: 686-691
  CrossrefPubMedGoogle Scholar
• 65 Lima LH, Zweifel SA, Engelbert M et al. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy. Retina (Philadelphia, Pa ) 2009; 29: 1213-1217
  CrossrefPubMedGoogle Scholar
• 66 Pierozzi G. Same-day bilateral intravitreal injections. Fort Lauderdale, Florida: IOVS; 2012
  Google Scholar
• 67 Shah M, Amoaku WM. Same-day consecutive bilateral intravitreal injections of ranibizumab for the treatment of bilateral active choroidal neovascularization in age-related macular degeneration. Acta Ophthalmol 2012; 90: e491-e493
  CrossrefPubMedGoogle Scholar
• 68 Davis RP, Schefler AC, Murray TG. Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration. Clin Ophthalmol Auckl NZ 2010; 4: 703-707
  PubMedGoogle Scholar
• 69 Mahajan VB, Elkins KA, Russell SR et al. Bilateral intravitreal injection of antivascular endothelial growth factor therapy. Retina (Philadelphia, Pa ) 2011; 31: 31-35
  CrossrefPubMedGoogle Scholar
• 70 Rosen ES. Immediate sequential bilateral cataract surgery. J Cataract Refract Surg 2012; 38: 1707-1708
  CrossrefPubMedGoogle Scholar
• 71 Serrano-Aguilar P, Ramallo-Fariña Y, Cabrera-Hernández JM et al. Immediately sequential versus delayed sequential bilateral cataract surgery: safety and effectiveness. J Cataract Refract Surg 2012; 38: 1734-1742
  CrossrefPubMedGoogle Scholar
• 72 Sparrow JM. Monte-Carlo simulation of random clustering of endophthalmitis following cataract surgery. Eye 2007; 21: 209-213
  CrossrefPubMedGoogle Scholar
• 73 Mitchell P, Bandello F, Schmidt-Erfurth U et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625
  CrossrefPubMedGoogle Scholar
• 74 Massin P, Bandello F, Garweg JG et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33: 2399-2405
  CrossrefPubMedGoogle Scholar
• 75 Lang GE, Berta A, Eldem BM et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology 2013; 120: 2004-2012
  CrossrefPubMedGoogle Scholar
• 76 Campochiaro PA, Brown DM, Pearson A et al. Long-term benefit os sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011; 118: 626-635
  CrossrefPubMedGoogle Scholar
• 77 Campochiaro PA, Brown DM, Pearson A et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years inn patients with diabetic macular edema. Ophthalmology 2012; 119: 2125-2132
  CrossrefPubMedGoogle Scholar